461 related articles for article (PubMed ID: 17542047)
1. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Timdahl K; Carlsson A; Stening G
Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
[TBL] [Abstract][Full Text] [Related]
2. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
Meulien D; Huizar K; Brecher M
Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
7. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
8. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Fleischhacker WW; Lemmens P; van Baelen B
Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.
McIntyre RS; Brecher M; Paulsson B; Huizar K; Mullen J
Eur Neuropsychopharmacol; 2005 Oct; 15(5):573-85. PubMed ID: 16139175
[TBL] [Abstract][Full Text] [Related]
10. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Perez V; Cañas F; Tafalla M;
Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder.
Adler CM; Fleck DE; Brecher M; Strakowski SM
J Affect Disord; 2007; 100 Suppl 1():S15-22. PubMed ID: 17383737
[TBL] [Abstract][Full Text] [Related]
12. Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study.
Boidi G; Ferro M
Hum Psychopharmacol; 2007 Jul; 22(5):299-306. PubMed ID: 17487936
[TBL] [Abstract][Full Text] [Related]
13. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
14. Choosing an atypical antipsychotic.
Sussman N
Int Clin Psychopharmacol; 2002 Aug; 17 Suppl 3():S29-33. PubMed ID: 12570069
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
[TBL] [Abstract][Full Text] [Related]
16. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine has a direct effect on the negative symptoms of schizophrenia.
Tandon R
Hum Psychopharmacol; 2004 Dec; 19(8):559-63. PubMed ID: 15486960
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Devlin JW; Roberts RJ; Fong JJ; Skrobik Y; Riker RR; Hill NS; Robbins T; Garpestad E
Crit Care Med; 2010 Feb; 38(2):419-27. PubMed ID: 19915454
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
Mullen J; Jibson MD; Sweitzer D
Clin Ther; 2001 Nov; 23(11):1839-54. PubMed ID: 11768836
[TBL] [Abstract][Full Text] [Related]
20. Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia.
Tandon R
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S15-20. PubMed ID: 12832945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
